Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

Vertex Pharma receives CHMP positive opinion for label expansion of Kaftrio in combination with ivacaftor: London Tuesday, March 4, 2025, 14:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

In the realm of gene-editing therapies, Vertex has launched Casgevy, an ex-vivo gene-edited cell therapy for the severe blood ...

Kaftrio is the first drug that works in patients with the F508del and MF mutations, who account for around 90% of the overall CF population, and in trials led to improved lung function as well as ...

Strong demand for its CF therapy, Trikafta/Kaftrio, delivered $10.2 billion in revenue for the year. We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its ...

Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.

Cystic Fibrosis (CF) is an incurable, life-limiting condition, affecting over 11,300 people in the UK costing the NHS millions in care.